Actively Recruiting
Study of Arikayce Inhalation with Standard Therapy to Treat Mycobacterium Xenopi Lung Infection in Adults
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-11-19
190
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating treatments for Mycobacterium xenopi MX lung disease, which is challenging to treat and affects many patients with chronic lung conditions or weakened immune systems. Treatment typically lasts around 18 months, based on sputum conversion, but outcomes remain poor. MX is rare in the USA but more common in France. Amikacin, an antibiotic, showed promise in animal models but was previously limited due to toxicity when given intravenously. A new form, amikacin liposome inhalation suspension ARIKAYCE4, delivers the drug via inhalation, targeting lung cells and reducing systemic exposure. ARIKAYCE4 has already been tested in lung infections caused by related bacteria.
CONDITIONS
Brief Title
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Research Team
C
Claire ANDREJAK, Pr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
